Free shipping on all orders over $ 500

Fruquintinib

Cat. No. M7554
Fruquintinib Structure
Synonym:

HMPL-013

Size Price Availability Quantity
5mg USD 60  USD60 In stock
10mg USD 90  USD90 In stock
25mg USD 140  USD140 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: Fruquintinib demonstrates potent inhibition on VEGF-A dependent KDR phosphorylation in HEK293-KDR cells and VEGF-A induced proliferation in primary HUVECs with IC50s of 0.6±0.2 nM and 1.7 nM, respectively. Similarly, potent VEGFR3 attenuation by fruquintinib is observed in primary HLECs, with IC50s of 1.5 nM and 4.2 nM for VEGF-C stimulated VEGFR3 phosphorylation and proliferation, respectively. Fruquintinib suppresses the tube branching, tube length and area in a concentration-dependent manner. The tubule length of primary HUVECs decreased by 74% and 94% at 0.03 and 0.3 μM of fruquintinib, respectively. Fruquintinib inhibits HUVEC tubule growth and CAM angiogenesis. Tube formation is suppressed significantly after treatment with fruquintinib at 0.3 μM for 18 hours.

In vivo: Gastric cancer BGC-823 model is found to be most sensitive to fruquintinib. In this model, fruquintinib inhibits tumor growth by 62.3% and 95.4∼98.6%, at 0.5 and 2 mg/kg once daily dosing, respectively. When the dose is elevated to 5 mg/kg and 20 mg/kg, the tumors regress by 24.1% and 48.6%, respectively. The level of anti-tumor growth activity of fruquintinib varies in different tumor xenograft models. Fruquintinib significantly decreases the micro-vessel density even at the lowest dose of 0.8 mg/kg.

Protocol (for reference only)
Cell Experiment
Cell lines Primary HUVECs or HLECs
Preparation method Primary HUVECs or HLECs in exponential phase are suspended in 100 μL of RPMI-1640 media containing 0.5% FBS, and seeded at 5000 cell/well in 96-well plates pre-coated with 0.2% gelatin or fibronectin, and incubated overnight in a 5% CO2, 37°C incubator. Fruquintinib and VEGF-A165 or VEGF-C (50 ng/mL) are added and incubated for 48 hours. Viability of the cells is determined using CCK-8 assay format
Concentrations 10 mM
Incubation time 48 hours
Animal Experiment
Animal models Mice
Formulation aqueous 0.5% CMC-Na (w/v)
Dosages 0.5-20 mg/kg
Administration orally
Chemical Information
Molecular Weight 393.39
Formula C21H19N3O5
CAS Number 1194506-26-7
Solubility (25°C) 7.75 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Tampellini M, et al. Expert Opin Investig Drugs. Novel anti-angiogenic therapeutic strategies in colorectal cancer.

[2] Sun Q, et al. Cancer Biol Ther. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.

Related VEGFR/PDGFR Products
Oglufanide

Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus.

KLTWQELYQLKYKGI

KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF.

Protein LMWP

Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity.

CBO-P11

CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis.

Aiphanol

Aiphanol is an extract of Poria cocos that directly targets and inhibits VEGFR2 and COX2, thereby blocking angiogenesis and tumor growth.

  Catalog
Abmole Inhibitor Catalog




Keywords: Fruquintinib, HMPL-013 supplier, VEGFR/PDGFR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.